Dermatitis News and Research

Latest Dermatitis News and Research

Discovery opens new therapeutic avenue for chronic skin condition affecting millions

Researchers from the La Jolla Institute for Allergy and Immunology have revealed a critical player in the cellular interactions leading to eczema - a chronic inflammatory skin condition affecting more than 14 million U.S. children and adults.

10 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Asthma link to mood disorders strengthened

Results from a prospective study support a relationship between asthma in adolescence and future diagnosis of mood disorders.

24 Dec 2013

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Sanofi and Regeneron Pharmaceuticals, Inc. today announced an innovative collaboration with the American College of Cardiology focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is known to contribute to circulating low-density lipoprotein cholesterol (LDL-C) levels. Alirocumab is being co-developed by Sanofi and Regeneron.

19 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Crealta to acquire all assets of Savient Pharmaceuticals

Savient Pharmaceuticals, Inc. ("Savient") announced that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds of approximately $120.4 million.

11 Dec 2013

Autumn-born children prone to asthma

Month of birth closely correlates with the prevalence of bronchial asthma, a major study of Taiwanese children has found.

5 Dec 2013

New evidence-based guidelines for diagnosis and assessment of atopic dermatitis

The American Academy of Dermatology (Academy) has released new evidence-based guidelines for the diagnosis and assessment of atopic dermatitis based on an extensive review of the scientific literature on this chronic skin condition characterized by itchy red patches of skin.

5 Dec 2013

Pediatric dermatologists offer tips for treating skin ailments

As parents across the Chicago area prepare to take that perfect holiday photo to send to family and friends, they may want to consider more than just getting their kids to smile and look at the camera.

28 Nov 2013

Icahn School of Medicine receives $2.7M to investigate narrow pathway targeted immune therapy

The National Institutes of Health has awarded a research team at the Icahn School of Medicine at Mount Sinai $2.7 million to study systemic treatments for patients with moderate to severe atopic dermatitis (AD), also known as eczema.

26 Nov 2013

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has received approval for the treatment of Macular Edema Following Central Retinal Vein Occlusion from the Japanese Ministry of Health, Labour and Welfare.

22 Nov 2013

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Atopix Therapeutics Ltd, a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the recruitment of the first patient in a six month Phase 2 clinical trial of its lead compound OC459 in moderate-to-severe atopic dermatitis (eczema).

19 Nov 2013

Bleach solution could provide new way to treat skin damage

Processes that age and damage skin are impeded by dilute bleach solution, according to a new study by researchers at the Stanford University School of Medicine.

16 Nov 2013

Dermalogix awarded SBIR Phase II grant to develop topical drug candidate for atopic dermatitis

Signum Dermalogix, Inc. announced that the National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the company a Small Business Innovation Research Phase II grant totaling $1.6 million for the development of a topical drug candidate for atopic dermatitis.

15 Nov 2013

Index predicts asthma in high-risk preschool children

Researchers have shown that the modified Asthma Predictive Index has high predictive value for future asthma development, when applied in the first 3 years of life.

12 Nov 2013

Gene mutations responsible for persistent AD in African American children

Two specific genetic variations in people of African descent are responsible for persistent atopic dermatitis (AD), an itchy, inflammatory form of the skin disorder eczema. A new report by researchers in the Perelman School of Medicine at the University of Pennsylvania found that loss-of-function mutations to Filaggrin-2 (FLG2), a gene that creates a protein responsible for retaining moisture and protecting the skin from environmental irritants, were associated with atopic dermatitis in African American children.

12 Nov 2013

Polyphor, Roche agree to develop and commercialize antibiotic for bacterial infections

Polyphor Ltd, a privately held pharmaceutical company, and Roche announced today that they have entered into an exclusive worldwide license agreement to develop and commercialize Polyphor's investigational macrocycle antibiotic, POL7080, for patients suffering from bacterial infections caused by Pseudomonas aeruginosa.

4 Nov 2013

Dermatitis News and Research

Latest Dermatitis News and Research

Discovery opens new therapeutic avenue for chronic skin condition affecting millions

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Asthma link to mood disorders strengthened

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Crealta to acquire all assets of Savient Pharmaceuticals

Autumn-born children prone to asthma

New evidence-based guidelines for diagnosis and assessment of atopic dermatitis

Pediatric dermatologists offer tips for treating skin ailments

Icahn School of Medicine receives $2.7M to investigate narrow pathway targeted immune therapy

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Bleach solution could provide new way to treat skin damage

Dermalogix awarded SBIR Phase II grant to develop topical drug candidate for atopic dermatitis

Index predicts asthma in high-risk preschool children

Gene mutations responsible for persistent AD in African American children

Polyphor, Roche agree to develop and commercialize antibiotic for bacterial infections

New finding could help lead to better treatments for eczema

Dermatologists provide list of specific treatments, procedures not required for medical care

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Dermatitis News and Research

Latest Dermatitis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in